Stock 532305 IND-SWIFT LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Ind-Swift Laboratories Limited Bombay S.E.

Equities

532305

INE915B01019

Market Closed - Bombay S.E.
Other stock markets
 06:00:54 2024-07-12 am EDT 		5-day change 1st Jan Change
134.4 INR +0.07% Intraday chart for Ind-Swift Laboratories Limited +1.09% +29.32%
Jul. 12 Ind-Swift Laboratories Limited Approves the Expansion of Business of the Company or the Wholly Owned Subsidiaries CI
Jun. 27 Ind-Swift Laboratories Limited announced that it expects to receive funding from Essix Biosciences Limited, Hcp Investments, Zeal Global Opportunities Fund CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ind-Swift Laboratories Limited Approves the Expansion of Business of the Company or the Wholly Owned Subsidiaries
CI
Ind-Swift Laboratories Limited announced that it expects to receive funding from Essix Biosciences Limited, Hcp Investments, Zeal Global Opportunities Fund
CI
Ind-Swift Laboratories Ltd. Announces Incorporation Under Regulation 30 Regarding Incorporation of ISLL Middle East L.L.C-FZ
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
CI
Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai
MT
Ind-Swift Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary
CI
Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer
CI
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer
CI
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture
CI
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited.
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing
MT
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research
CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023
CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.
CI
IndiaRF to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 1,650 Crores
AQ
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories
MT
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million
RE
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INDSWFTLAB Stock
  4. 532305 Stock
  5. News Ind-Swift Laboratories Limited